Conquering Diseases

Study Of An Investigational Combination Therapy For Early Stage Hodgkin Lymphoma

Description

Seeking people aged 5-60 newly diagnosed with early (Stage I or II) Hodgkin lymphoma that has not yet been treated for a study comparing the effect of adding immunotherapy to the standard chemotherapy to the standard chemotherapy alone.

Overview

After receiving 2 months of standard ABVD chemotherapy treatment, participants in this study will be randomly assigned to

What we're hoping for

We are comparing the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone for people with stage I and II classical Hodgkin lymphoma.

Additional Information

ClinicalTrials.gov Identifier: NCT05675410

 Principal Investigator

Stefanie  Lowas, MD

UMass Chan Medical School

 Study Contact

The Cancer  Research Office

508-856-3216

Cancer.research@umassmed.edu

 Location

UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989